BINVS Stock Overview
A clinical-stage company, discovers, researches, and develops novel immuno-modulatory antibodies for the treatment of cancer in Sweden, Europe, the United States, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
BioInvent International AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 34.75 |
| 52 Week High | SEK 39.45 |
| 52 Week Low | SEK 34.70 |
| Beta | 0.30 |
| 11 Month Change | 0% |
| 3 Month Change | -3.87% |
| 1 Year Change | n/a |
| 33 Year Change | -4.40% |
| 5 Year Change | -31.86% |
| Change since IPO | -43.27% |
Recent News & Updates
Recent updates
Shareholder Returns
| BINVS | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 0% | 0.3% | 2.2% |
| 1Y | n/a | -18.3% | 8.0% |
Return vs Industry: Insufficient data to determine how BINVS performed against the UK Biotechs industry.
Return vs Market: Insufficient data to determine how BINVS performed against the UK Market.
Price Volatility
| BINVS volatility | |
|---|---|
| BINVS Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 9.6% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 10.3% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: BINVS has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine BINVS's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 93 | Martin Welschof | www.bioinvent.com |
BioInvent International AB (publ), a clinical-stage company, discovers, researches, and develops immuno-modulatory antibodies for the treatment of cancer in Sweden, Europe, the United States, Japan, and internationally. Its lead drug candidate is BI-1206 for the treatment of non-Hodgkin lymphoma and solid tumors. The company also develops tumor associated myeloid cells; cancer-associated regulatory T cells, which modulate the immune system; BT-001 in solid tumors; and BI-1808 and BI-1910, which are anti-TNFR2 antibodies for the treatment of solid tumors and cutaneous T-cell lymphoma.
BioInvent International AB (publ) Fundamentals Summary
| BINVS fundamental statistics | |
|---|---|
| Market cap | SEK 2.07b |
| Earnings (TTM) | -SEK 42.93m |
| Revenue (TTM) | SEK 310.39m |
6.7x
P/S Ratio-48.3x
P/E RatioIs BINVS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BINVS income statement (TTM) | |
|---|---|
| Revenue | SEK 310.39m |
| Cost of Revenue | SEK 0 |
| Gross Profit | SEK 310.39m |
| Other Expenses | SEK 353.32m |
| Earnings | -SEK 42.93m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
Feb 22, 2023
| Earnings per share (EPS) | -0.65 |
| Gross Margin | 100.00% |
| Net Profit Margin | -13.83% |
| Debt/Equity Ratio | 0% |
How did BINVS perform over the long term?
See historical performance and comparison